Skip to content

Transcriptomics-based research on the pathogenesis of cervical ossification of posterior longitudinal ligament and new clinical precision diagnosis and treatment technology

Transcriptomics-based research on the pathogenesis of cervical ossification of posterior longitudinal ligament and new clinical precision diagnosis and treatment technology

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036203
Enrollment
Unknown
Registered
2020-08-21
Start date
2020-08-17
Completion date
Unknown
Last updated
2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ossification of posterior longitudinal ligament

Interventions

the cervical posterior longitudinal ligament ossification :Nil
the cervical posterior longitudinal ligament without ossification group:Nil

Sponsors

Shanghai Changzheng Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Criteria for inclusion in the cervical posterior longitudinal ligament ossification group: 1. Single-segment or multi-segment ossification of the posterior longitudinal ligament of the cervical spine confirmed by CT three-dimensional reconstruction, or at least combined with two diseases of posterior longitudinal ligament ossification, ligamentum flavum ossification, and diffuse bone hyperplasia; 2. Between 18 and 75 years old, no gender limit; 3. Symptoms of spinal cord or nerve root compression, surgical indications and the patient's willingness to operate; 4. Willing to sign informed consent. Criteria for inclusion in the cervical posterior longitudinal ligament without ossification group: 1. No posterior longitudinal ligament ossification of the spine; only degeneration and herniated intervertebral disc; 2. Between 18 and 75 years old, no gender limit; 3. Symptoms of spinal cord or nerve root compression, surgical indications and the patient's willingness to operate; 4. Willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with uncontrolled hypertension, diabetes or other severe heart and lung diseases and other surgical contraindications; 2. Very poor coagulation function, platelets lower than 20 * 10^9/L or INR >= 3.5; 3. Patients diagnosed or suspected of having malignant tumor; 4. Pregnant and lactating women or women whose pregnancy is not excluded; 5. Patients suffering from mental illness; 6. Other researchers think it is not suitable for participants.

Design outcomes

Primary

MeasureTime frame
Immunohistochemical staining results;

Countries

China

Contacts

Public ContactYang Lili

Shanghai Changzheng Hospital

orthoyang@sina.com+86 13611770660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026